Perfil
Danute M.
Bankaitis-Davis worked as a Research Scientist at Amgen, Inc. from 1992 to 1998.
She also worked as a Principal at Syntex Corp.
and as an Executive Vice President at Source Precision Medicine, Inc. Dr. Bankaitis-Davis received her undergraduate and graduate degrees from Cleveland State University and her doctorate degree from The University of North Carolina at Charlotte.
Antiguos cargos conocidos de Danute M. Bankaitis-Davis.
| Empresas | Cargo | Fin |
|---|---|---|
| AMGEN INC. | Director Técnico/Científico/I+D | 01/01/1998 |
| Syntex Corp. | Corporate Officer/Principal | - |
Source Precision Medicine, Inc.
 Source Precision Medicine, Inc. Medical SpecialtiesHealth Technology Source Precision Medicine, Inc. develops and commercializes diagnostic biomarker panels. It develops an integrated molecular diagnostic system, which includes quantitative polymerase chain reaction assays, target specific gene expression ranges, and latent class and proprietary enumeration methodologies that measure vital signs of the cell. Its assays and tests measure RNA-transcript-based gene expression in whole blood using quantitative polymerase chain reaction optimized for clinical use in a commercial setting. The company was founded in 1998 and is headquartered in Boulder, CO. | Corporate Officer/Principal | - |
Formación de Danute M. Bankaitis-Davis.
| The University of North Carolina at Charlotte | Doctorate Degree |
| Cleveland State University | Graduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| AMGEN INC. | Health Technology |
| Empresas privadas | 2 |
|---|---|
Source Precision Medicine, Inc.
Source Precision Medicine, Inc. Medical SpecialtiesHealth Technology Source Precision Medicine, Inc. develops and commercializes diagnostic biomarker panels. It develops an integrated molecular diagnostic system, which includes quantitative polymerase chain reaction assays, target specific gene expression ranges, and latent class and proprietary enumeration methodologies that measure vital signs of the cell. Its assays and tests measure RNA-transcript-based gene expression in whole blood using quantitative polymerase chain reaction optimized for clinical use in a commercial setting. The company was founded in 1998 and is headquartered in Boulder, CO. | Health Technology |
| Syntex Corp. | Health Technology |
- Bolsa de valores
- Insiders
- Danute M. Bankaitis-Davis
